Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, novembre 02
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Evolent Health Inc
EVH
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$4.45
0.15
3.49%
Ult. Agg.: Nov 2, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 3 giorni da adesso in gio nov 5th, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 3 giorni alle 8:30 AM
Clicca per vedere il webcast
Evolent Health Financials
Evolent Health (EVH) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est
Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
Benzinga Newsdesk
PRO
Evolent Health Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $652.520M Beat $597.997M Estimate
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 120 percent increase over losses of $(0.10) per share from the same
Benzinga Newsdesk
PRO
Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est.
Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.400 billion-$2.600 billion vs $2.487 billion estimate.
Benzinga Newsdesk
PRO
Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate.
Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 133.33 percent decrease over earnings of $0.06 per share from the
Benzinga Newsdesk
PRO
Evolent Health Sees FY2026 Sales $2.400B-$2.600B vs $2.379B Est
Evolent Health (NYSE:EVH) sees FY2026 sales of $2.400 billion-$2.600 billion vs $2.379 billion analyst estimate.
Benzinga Newsdesk
PRO
Evolent Health Q4 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $468.719M Beat $468.701M Estimate
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 37.93 percent. This is a 500 percent increase over losses of $(0.02) per share from the same
Benzinga Newsdesk
